EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Vascular effects of SGLT2 inhibitors: evidence and mechanisms

Beatriz R Góes-Santos iD, Paulo C Castro iD, Adriana C C Girardi iD, Lígia M Antunes-Correa iD, Ana P Davel iD

American Journal of Physiology-Cell Physiology · 01.10.2025 · 329 (4) · C1150-C1160

DOI: 10.1152/ajpcell.00569.2025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.10.2025. Verfasst von Beatriz R Góes-Santos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Educação Física, Universidade Estadual de Campinas (FEF-UNICAMP), Campinas, Brazil. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) were initially developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM). However, robust clinical evidence has demonstrated that their therapeutic benefits extend beyond glycemic control. SGLT2i reduce hospitalization for heart failure (HF), slow the progression of chronic kidney disease (CKD), and provide cardiorenal protection even in individuals without diabetes but with cardiovascular disease. These pleiotropic effects include favorable actions on both macrovascular and microvascular functions, which may contribute to their broad cardiovascular, renal, and metabolic benefits. Although the mechanisms underlying these vascular effects remain incompletely understood, they appear to involve both hemodynamic modulation and direct cellular actions that vary according to disease context and vascular bed. Elucidating these mechanisms is essential to refining therapeutic strategies and guiding optimal patient selection. This short review highlights the multifaceted vascular benefits of SGLT2i, summarizing current clinical and mechanistic insights into their vascular actions, with a particular mention of their role in the context of malignancy. SGLT2i contribute to improved cell viability, proliferation, and angiogenesis by attenuating endothelial cell apoptosis, ferroptosis, and pyroptosis, while also influencing inflammatory and oxidative signaling pathways, and enhancing eNOS phosphorylation and deacetylation. In addition to their endothelial effects, we explore the impact of SGLT2i on vascular smooth muscle cells and perivascular nerves, which can lead to reduced vascular stiffness, calcification, and improved vasodilation. Sex-specific differences in clinical outcomes and mechanisms are also discussed. Finally, we identify key areas for future investigation to better harness the full therapeutic potential of SGLT2i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansAnimals

Stichwörter der Autor:innen

SGLT2 inhibitorscardiovascular diseaseendothelial cellkidney diseasevascular smooth muscle cell

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Faculdade de Educação Física, Universidade Estadual de Campinas (FEF-UNICAMP), Campinas, Brazil.
  • Departamento de Cardiopneumologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Obesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
  • Instituto de Biologia, Universidade Estadual de Campinas (IB-UNICAMP), Campinas, Brazil.

ORCID-Profile: Beatriz R Góes-Santos, Paulo C Castro, Adriana C C Girardi, Lígia M Antunes-Correa, Ana P Davel

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Zitieren

APA

Góes-Santos, B. R., Castro, P. C., Girardi, A. C. C., Antunes-Correa, L. M., & Davel, A. P. (2025). Vascular effects of SGLT2 inhibitors: evidence and mechanisms. American Journal of Physiology-Cell Physiology, 329(4), C1150-C1160. https://doi.org/10.1152/ajpcell.00569.2025

Vancouver

Góes-Santos BR, Castro PC, Girardi ACC, Antunes-Correa LM, Davel AP. Vascular effects of SGLT2 inhibitors: evidence and mechanisms. American Journal of Physiology-Cell Physiology. 2025;329(4):C1150-C1160. doi:10.1152/ajpcell.00569.2025

BibTeX
@article{GesSantos2025,
  author = {Góes-Santos, Beatriz R and Castro, Paulo C and Girardi, Adriana C C and Antunes-Correa, Lígia M and Davel, Ana P},
  title = {Vascular effects of SGLT2 inhibitors: evidence and mechanisms},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2025},
  volume = {329},
  number = {4},
  pages = {C1150--C1160},
  doi = {10.1152/ajpcell.00569.2025}
}
Kostenlos starten →